% | $
Quotes you view appear here for quick access.

CytRx Corporation Message Board

  • biotuesday biotuesday Oct 15, 2013 7:45 AM Flag

    BioTuesdays: CytRx awaiting soft tissue sarcoma data in December

    What if it were possible to deliver a broad range of potent cancer drugs more optimally, enhancing both their safety and efficacy?

    That’s the question CytRx (NASDAQ:CYTR) hopes to answer this December when it plans to report top-line Phase 2b data from a global clinical trial of its lead drug, aldoxorubicin, as a first-line treatment for soft tissue sarcoma, where tumors develop in soft tissue such as muscle, fat, blood vessels, nerves, tendons and in the lining of joints.

    “Our clinical and preclinical evidence thus far supports our belief that aldoxorubicin and our technology platform have the potential to dramatically improve traditional chemotherapy by allowing cancer patients to receive more drug, up to 3.5-to-four times more drug, and have fewer side effects,” president and CEO Steven Kriegsman says in an interview with BioTuesdays.

    “Aldoxorubicin is just the tip of the iceberg, since we are making better versions of several anti-cancer drugs,” he adds.......

    ....see BioTuesdays for the rest of this week's feature on CYTR....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.66-0.06(-1.61%)Jul 2 4:00 PMEDT